


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. **(Currently Amended)** A compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of C₃₋₁₄ cycloalkyl, 3-14 membered heterocycloalkyl, C₄₋₁₄ cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, heteroaryl; the cyclic moiety being optionally substituted with 1-3 substituents, each of which is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, and alkylsulfonyl;

each of X¹ and X², independently, is O or S;

Y¹ is -CH₂-, -O-, -S-, -N(R^a)-, -N(R^a)-C(O)-O-, -O-C(O)-N(R^a)-, -N(R^a)-C(O)N(R^b)-, -O-C(O)-O-, or a bond; each of R^a and R^b, independently being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

Y² is CH₂ ~~or a bond~~;

L is a straight C₃₋₁₂ hydrocarbon chain optionally containing at least one double bond adjacent to ~~Y¹ or Y², at least one triple bond, or at least one double bond and one triple bond~~; said hydrocarbon chain being optionally substituted with C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, hydroxyl, halo, amino, nitro, C₃₋₅ cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, -N(R^c)-, -N(R^c)-C(O)-O-, -O-C(O)-(R^c)-, -N(R^c)-C(O)-N(R^d)-, or -O-C(O)-O-; each of R^c and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; that when L contains three double bonds, said hydrocarbon chain is further substituted with C₂₋₄ alkenyl, C₂₋₄ alkynyl,

C_{1-4} alkoxy, hydroxyl, halo, amino, nitro, C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkylcarbonyl, or formyl; and further provided that when L is C_{3-7} ~~C_4 or C_5~~ and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y^1 is not a bond or $-CH_2-$, and Y^2 is $-CH_2-$;

provided that when L is C_4 , A is C_{3-14} cycloalkyl then $[[Y_1]] Y^1$ is not CH_2 ; and further provided that when L is C_4 containing two double bonds, and is ω -substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl;

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, 5, 5-diphenylpent-4-enoic acid, 2,2-dichloro-12-phenyl-11-dodecenoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-tridecenoic acid.

2. **(Original)** The compound of claim 1, wherein X^1 is O.

3. **(Original)** The compound of claim 1, wherein X^2 is O.

4. **(Original)** The compound of claim 1, where each of X^1 and X^2 is O.

5. **(Previously Presented)** The compound of claim 1, wherein Y^1 is $-CH_2-$, $-O-$, $-N(R^a)-$, or a bond.

6. **(Canceled)**

7. **(Previously Presented)** The compound of claim 1, wherein L is an unsaturated C_{4-8} hydrocarbon containing at least one double bond and no triple bond, said unsaturated hydrocarbon chain being optionally substituted with C_{1-2} alkoxy, hydroxyl, $-NH_2$, $-NH(C_{1-2} \text{ alkyl})$, or $-N(C_{1-2} \text{ alkyl})_2$, or $-N(C_{1-2} \text{ alkyl})_2$.

8. **(Original)** The compound of claim 7, wherein the double bond is in trans configuration.

9-11. **(Canceled)**

12. **(Original)** The compound of claim 1, wherein A is phenyl, naphthyl, indanyl, or tetrahydronaphthyl.

13. **(Previously Presented)** The compound of claim 1, wherein A is phenyl optionally substituted with 1-3 substituents each of which is independently selected from the group consisting of alkyl, alkenyl, hydroxyl, hydroxylalkyl, halo, haloalkyl, and amino.


14-15. **(Canceled)**

16. **(Previously Presented)** The compound of claim 13, wherein L is an unsaturated C₄₋₈ hydrocarbon chain containing only double bonds in trans configuration, said unsaturated hydrocarbon chain being optionally substituted with C₁₋₂ alkoxy, hydroxyl, -NH₂, -NH(C₁₋₂ alkyl), or -N(C₁₋₂ alkyl)₂.

17. **(Previously Presented)** The compound of claim 16, wherein X¹ is O; X² is O; and Y¹ is -CH₂-, -O-, -N(R^a)-, or a bond.

18-21. **(Canceled)**

22. **(Currently Amended)** A compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of aryl and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, hydroxylalkyl, or amino;

each of X¹ and X², independently, is O or S;

Y¹ is -CH₂-, -O-, -S-, -N(R^a)-, -N(R^a)-C(O)-O-, -O-C(O)-N(R^a)-, -N(R^a)-C(O)-N(R^b)-,

-O-C(O)-O-, or a bond; each of R^a and R^b, independently, being hydrogen, alkyl, hydroxylalkyl, or haloalkyl;

Y² is CH₂ ~~or a bond~~;

L is a straight C₃₋₁₂ hydrocarbon chain optionally containing at least one double bond adjacent to ~~Y¹ or Y², at least one triple bond, or at least one double bond and one triple bond~~; said hydrocarbon chain being optionally substituted with C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, or amino, and further optionally interrupted by -O- or -N(R^c)-, where R^c is hydrogen, alkyl, hydroxylalkyl, or haloalkyl; provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; that when L contains three double bonds, said hydrocarbon chain is substituted with C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, or amino; and further provided that when L is ~~C₄ or C₅~~-C₃₋₇ and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y¹ is not a bond or -CH₂-, and Y² is -CH₂-; or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, 5, 5-diphenylpent-4-enoic acid, 2,2-dichloro-12-phenyl-11-dodecenoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-tridecenoic acid.


23-24. (Canceled)

25. (Previously Presented) The compound of claim 22, wherein L is an unsaturated C₄₋₈ hydrocarbon chain containing only double bonds in trans configuration, said unsaturated hydrocarbon chain being optionally substituted with C₁₋₂ alkoxy, hydroxyl, -NH₂, -NH(C₁₋₂ alkyl), or -N(C₁₋₂ alkyl)₂.

26. (Previously Presented) The compound of claim 25, where in X¹ is O; X² is O; and Y¹ is -CH₂-, -O-, -N(R^a)-, or a bond.

27-79. (Canceled)

80. (Currently Amended) A pharmaceutical composition, comprising compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of C₃₋₁₄ cycloalkyl, 3-14 membered heterocycloalkyl, C₄₋₁₄ cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, and heteroaryl; the cyclic moiety being optionally substituted with 1-3 substituents, each of which is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, and alkylsulfonyl;

each of X¹ and X², independently, is O or S;

Y¹ is -CH₂-, -O-, -S-, -N(R^a)-, -N(R^a)-C(O)-O-, -O-C(O)-N(R^a)-, -N(R^a)-C(O)-N(R^b)-, -O-C(O)-O-, or a bond; each of R^a and R^b independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

Y² is CH₂ or a bond;

L is a straight C₅₋₁₂ hydrocarbon chain containing at least one double bond adjacent to ~~Y¹ or Y²~~, ~~or at least one double bond and one triple bond~~; said hydrocarbon chain being optionally substituted with C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, hydroxyl, halo, amino, nitro, cyano, C₃₋₅ cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkyloxycarbonyl, C₁₋₄ alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, -N(R^c)-, -N(R^c)-C(O)-O-, -O-C(O)-N(R^c)-, -N(R^c)-C(O)-N(R^d)-, or -O-C(O)-O-; each of R^c and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

provided that when L is C₄, A is C₃₋₁₄ cycloalkyl then Y₁ is not CH₂; and further provided that when L is C₄ containing two double bonds, and is ω-substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl; further provided that when L is ~~C₄ or C₅~~ C₃₋₇ and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y¹ is not a bond or -CH₂-, and Y² is -CH₂-;

or a salt thereof; and

a pharmaceutically acceptable carrier, wherein the compound is not 8-phenyl-5-octenoic

acid, 6-phenyl-5-hexenoic acid, 5, 5-diphenylpent-4-enoic acid, 2,2-dichloro-12-phenyl-11-dodecenoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-tridecenoic acid.

81. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein X^1 is O.

82. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein X^2 is O.

83. **(Previously Presented)** The pharmaceutical composition of claim 80, where each of X^1 and X^2 is O.

84. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein Y^1 is $-\text{CH}_2-$, $-\text{O}-$, $-\text{N}(\text{R}^a)-$, or a bond.

85. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein L is an unsaturated C_{5-8} hydrocarbon chain containing at least one double bond and no triple bond, said unsaturated hydrocarbon chain being optionally substituted with C_{1-2} alkoxy, hydroxyl, $-\text{NH}_2$, $-\text{NH}(\text{C}_{1-2} \text{ alkyl})$, or $-\text{N}(\text{C}_{1-2} \text{ alkyl})_2$, or $-\text{N}(\text{C}_{1-2} \text{ alkyl})_2$.

86. **(Previously Presented)** The pharmaceutical composition of claim 85, wherein the double bond is in trans configuration.

87. **(Previously Presented)** The pharmaceutical composition of claim 80 wherein A is phenyl, naphthyl, indanyl, or tetrahydronaphthyl.


88. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein A is phenyl optionally substituted with 1-3 substituents, each of which is independently selected from the group consisting of alkyl, alkenyl, hydroxyl, hydroxylalkyl, halo, haloalkyl and amino.

89. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein L is an unsaturated C_{5-8} hydrocarbon chain containing only double bonds in trans configuration, said

unsaturated hydrocarbon chain being optionally substituted with C₁₋₂ alkoxy, hydroxyl, -NH₂, -NH(C₁₋₂ alkyl), or -N(C₁₋₂ alkyl)₂.

90. **(Previously Presented)** The pharmaceutical composition of claim 89, wherein X¹ is O; X² is O; and Y¹ is -CH₂-, -O-, -N(R^a)-, or a bond.

91. **(Currently Amended)** A compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of C₃₋₁₄ cycloalkyl, 3-14 membered heterocycloalkyl, C₄₋₁₄ cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl;

each of X¹ and X², independently, is O or S;

Y¹ is -CH₂-, -S-, -N(R^a)-, -N(R^a)-C(O)-O-, -O-C(O)-N(R^a)-, -N(R^a)-C(O)-N(R^b)-,

-O-C(O)-O-, or a bond; each of R^a and R^b, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

Y² is -CH₂- or a bond;

L is a straight C₃₋₆ hydrocarbon chain containing at least one double bond adjacent to Y¹ or Y², at least one triple bond, or at least one double bond and one triple bond; said hydrocarbon chain being substituted with C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, amino, nitro, C₃₋₅ cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, -N(R^c)-, -N(R^c)-C(O)-O-, -O-C(O)-N(R^c)-, -N(R^c)-C(O)-N(R^d)-, or -O-C(O)-O-; each of R^c and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or

haloalkyl;

provided that when L is C₄, A is C₃₋₁₄ cycloalkyl then Y₁ is not CH₂; and further provided that when L is C₄ containing two double bonds, and is ω-substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl; further provided that when L is ~~C₄~~ or ~~C₅~~ C₃₋₇ and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y¹ is not a bond or -CH₂-, and Y² is -CH₂-;
or a salt thereof, wherein the compound is not 5, 5-diphenylpent-4-enoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-tridecenoic acid.

92. **(Previously Presented)** The compound of claim 91, wherein X¹ is O.

93. **(Previously Presented)** The compound of claim 91, wherein X² is O.

94. **(Previously Presented)** The compound of claim 91, wherein each of X¹ and X² is O.

95. **(Canceled)**

96. **(Previously Presented)** The compound of claim 91, wherein L is an unsaturated C₄₋₆ hydrocarbon chain containing at least one double bond and no triple bond, said unsaturated hydrocarbon chain being substituted with C₁₋₂ alkoxy, -NH₂, -NH(C₁₋₂ alkyl), -N(C₁₋₂ alkyl)₂, -N(C₁₋₂ alkyl)₂, halo, or monocyclic aryl.

97. **(Previously Presented)** The compound of claim 96, wherein said double bond is in trans configuration.


98. **(Canceled)**

99. **(Previously Presented)** The compound of claim 91, wherein A is phenyl optionally substituted with alkyl, alkenyl, hydroxyl, hydroxylalkyl, halo, haloalkyl, or amino.

100. **(Previously Presented)** The compound of claim 91, wherein L is an unsaturated C₅₋₆ hydrocarbon chain containing double bonds only in trans configuration, said unsaturated hydrocarbon chain being substituted with C₁₋₂ alkoxy, -NH₂, -NH(C₁₋₂ alkyl), -N(C₁₋₂ alkyl)₂, halo, or monocyclic aryl.

101. **(Previously Presented)** The compound of claim 100, wherein X¹ is O; X² is O; and Y¹ is -CH₂-, -N(R^a)-, or a bond.

102. **(Currently Amended)** A compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of C₃₋₁₄ cycloalkyl, 3-14 membered heterocycloalkyl, C₄₋₁₄ cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, a heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl;

each of X¹ and X², independently, is O or S;

Y¹ is -CH₂-, -O-, -S-, -N(R^a)-, -N(R^a)-C(O)-O-, -O-C(O)-N(R^a)-, -N(R^a)-C(O)-N(R^b)-, -O-C(O)-O-, or a bond; each of R^a and R^b, independently being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;


Y² is CH₂ or a bond;

L is a straight C₃₋₇ hydrocarbon chain optionally containing at least one double bond adjacent to Y¹ or Y², ~~least one triple bond, or at least one double bond and one triple bond~~; said hydrocarbon chain being optionally substituted with C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, hydroxyl, halo, amino, nitro, C₃₋₅ cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkylcarbonyl, or formyl; and further being

optionally interrupted by -O-, -N(R^c)-, -N(R^c)-C(O)-O-, -O-C(O)-N(R^c)-, or -O-C(O)-O-; each of R^c and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; that when L contains three double bonds, said hydrocarbon chain is further substituted with C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, hydroxyl, halo, amino, nitro, C₃₋₅ cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkylcarbonyl, or formyl; and further provided that when L is C₄ or C₅ C₃₋₇ and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y¹ is not a bond or -CH₂-, and Y² is -CH₂-; provided that when L is C₄, A is C₃₋₁₄ cycloalkyl then Y₁ is not CH₂; and further provided that when L is C₄ containing two double bonds, and is ω-substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl;

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, or 5, 5-diphenylpent-4-enoic acid.

103. **(Currently Amended)** A compound of formula (I):



wherein

A is phenyl, naphthyl, indanyl, or tetrahydronaphthyl;
 each of X¹ and X², independently, is O or S;
 Y¹ is -CH₂-, -S-, -N(R^a)-C(O)-O-, -O-C(O)-N(R^a)-, -N(R^a)-C(O)-N(R^b)-, -O-C(O)-O-, or a bond;
 each of R^a and R^b, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;
 Y² is -CH₂- ~~or a bond~~;
 L is a straight C₃₋₆ hydrocarbon chain containing at least one double bond adjacent to ~~Y¹ or Y²~~, ~~at least one triple bond, or at least one double bond and one triple bond~~; said hydrocarbon chain being substituted with C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, amino, nitro, C₃₋₅ cycloalkyl, 3-5

membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkyloxycarbonyl, C₁₋₄ alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, -N(R^c)-, -N(R^c)-C(O)-O-, -O-C(O)-N(R^c)-, -N(R^c)-C(O)-N(R^d)-, or -O-C(O)-O-; each of R^c and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

provided that when L is C₄, A is C₃₋₁₄ cycloalkyl then Y₁ is not CH₂; and further provided that when L is C₄ containing two double bonds, and is ω-substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl; further provided that when L is ~~C₄~~ or ~~C₅~~ C₃₋₇ and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y¹ is not a bond or -CH₂-₂ and Y² is -CH₂-;

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid or 5, 5-diphenylpent-4-enoic acid.